JPMorgan analyst Tycho Peterson raised his price target for Repligen to $60 following meetings with management. The analyst came away with reinforced confidence in the company’s “strategic direction, strong competitive positioning, and sustainable growth momentum.” He remains positive on the long-term outlook of the bioprocessing market and keeps an Overweight rating on Repligen shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.